Everforth Inc quarterly report, Q3 FY2013

Business context and reporting period

The filing is On Assignment, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2013. The request identifies Everforth Inc., but the filing itself names On Assignment, Inc.; confirm the intended issuer. On Assignment provides staffing and placement services, with five reportable segments: Apex, Oxford, Life Sciences, Physician, and Healthcare.

Financial performance

Third quarter 2013 (versus third quarter 2012; dollars in millions except per-share data):

  • Revenue was $432.2 million, up 15.4%; gross profit was $130.6 million, up 13.0%.
  • Gross margin was 30.2%, down from 30.9%. Operating income was $36.9 million, up from $31.5 million.
  • Income from continuing operations was $20.2 million, versus $14.7 million; net income was $20.2 million, versus $15.5 million. Diluted EPS was $0.37, versus $0.29.
  • Interest expense, net, declined to $3.3 million from $6.0 million, reflecting lower debt and lower rates under the new credit facility.

Nine months ended September 30, 2013 (versus the comparable 2012 period):

  • Revenue was $1,239.3 million, up 55.5%; management reports pro forma revenue growth of 14.8% assuming Apex had been acquired at the start of 2011.
  • Gross profit was $368.5 million, with a 29.7% gross margin versus 31.7%. Operating income was $93.5 million, versus $56.4 million.
  • Income from continuing operations was $38.6 million, versus $25.8 million. Net income was $52.1 million, versus $28.4 million, including a $14.4 million after-tax gain on the Nurse Travel sale. Diluted EPS was $0.96, versus $0.62.
  • Interest expense, net, was $12.8 million versus $10.7 million. A $15.0 million write-off of old-facility loan costs was recorded in connection with the May 2013 refinancing.

Liquidity, debt, and cash flow

  • At September 30, cash and cash equivalents were $45.1 million; working capital was $193.3 million. Cash included $8.7 million held outside the United States, which the company said it did not intend to repatriate.
  • Total debt was approximately $357.8 million, down from approximately $426.6 million at December 31, 2012. The new $500 million credit facility comprises term A, term B, and revolving facilities; $122.5 million was available on the revolver.
  • The funded-debt-to-consolidated-EBITDA ratio was 2.16:1.00; the company reported compliance with its covenants. The facility’s maximum leverage limit steps down to 3.25:1.00 by June 30, 2015, and the debt is secured by substantially all company assets.
  • Nine-month operating cash flow was $73.9 million, versus $14.6 million. Investing activities provided $18.0 million, including $31.9 million net proceeds from the Nurse Travel sale; capital expenditures were $12.3 million. Financing activities used $74.5 million, principally reflecting debt repayments and refinancing.
  • Management expected cash, revolver availability, and operating cash flows to cover debt service, working capital, and capital expenditures for the next 12 months. Estimated full-year 2013 capital expenditures were approximately $17.3 million.

Material changes, outlook, and risks

  • Third-quarter revenue growth was led by IT staffing: Apex revenue rose 21.6% and Oxford 13.5%; together the IT segments generated approximately 96% of quarterly revenue growth. Physician and Healthcare revenue declined year over year.
  • Gross-margin pressure reflected a larger Apex mix, growth in lower-margin services, fewer direct-hire and conversion fees, and competitive pricing. Management also cited segment-specific mix and bill/pay spread effects.
  • Apex, acquired in May 2012, materially affects year-over-year comparability. Nine-month reported growth includes Apex for the full 2013 period but only from May 15 in 2012.
  • The Nurse Travel division was sold in February 2013 for $33.7 million cash; the sale generated a $14.4 million after-tax gain. Its results are presented as discontinued operations.
  • SG&A included earn-out reduction benefits and non-recurring expenses; the filing also reports acquisition-related and strategic-planning costs. The company disclosed an immaterial 2012 intangible-amortization error and provided corrected 2012 quarterly results.
  • No specific earnings or revenue guidance was provided. Business risks cited include economic demand, attracting and retaining staffing consultants and contract professionals, competition, growth management, information systems, and medical-malpractice and litigation matters. The company is partially self-insured for workers’ compensation and medical-malpractice claims; it said pending legal matters were not expected to materially affect its financial position, results, or cash flows.
  • Interest-rate exposure is material: management estimated that a 1 percentage-point rate change would change annual interest expense by approximately $3.3 million after interest-rate swaps and caps. The company reported no material change in foreign-currency market risk.

Important facts for investors to verify

  • Confirm the issuer identity: the supplied metadata says Everforth Inc., while the filing identifies On Assignment, Inc.
  • Assess whether underlying growth and profitability support reported results, separating Apex acquisition effects and the Nurse Travel sale gain from ongoing operations.
  • Track segment gross margins, particularly the continued pressure in Oxford, Life Sciences, Physician, and Healthcare, and the effect of Apex’s larger revenue mix.
  • Review debt amortization, covenant headroom, mandatory prepayment terms, and sensitivity to variable interest rates.
  • Monitor receivables and working-capital requirements, self-insurance reserves, earn-out assumptions and payments, and the performance conditions attached to stock awards.
  • Consider the effect of the 2012 amortization correction and restated comparative figures when evaluating year-over-year trends.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.